H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $25 from $36 and keeps a Buy rating on the shares following the Q2 report. The firm reduced estimates for the Ojemda launch.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN: